<DOC>
	<DOCNO>NCT00556296</DOCNO>
	<brief_summary>This study design assess efficacy safety NRP-104 administer daily dose 30mg , 50mg 70mg compare placebo treatment child age 6-12 year ADHD .</brief_summary>
	<brief_title>Phase 3 Randomized Double-Blind Placebo-Controlled Study NRP104 Children Aged 6-12 With ADHD</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
	<criteria>primary diagnosis ADHD combine subtype predominantly hyperactiveimpulsive subtype base psychiatric evaluation review DSMIV criterion function age appropriate level intellectually blood pressure measurement within 95th percentile gender , height age ECG result within normal range comorbid psychiatric diagnosis ( psychosis , bipolar illness , pervasive developmental disorder , severe obsessive compulsive disorder , severe depressive severe anxiety disorder ) symptomatic manifestation history seizure ( exclusive febrile seizure ) , tic disorder , family history Tourette 's disorder weigh less 55 lb ( 25 kg ) significantly overweight obese clinically significant ECG abnormality document allergy intolerance amphetamine</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>